p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus
- PMID: 11353048
- DOI: 10.1038/modpathol.3880324
p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus
Abstract
The aim of the present study was to characterize expression and mutation of p53 during the neoplastic progression from Barrett's esophagus to adenocarcinoma and to test the reliability of immunohistochemistry for p53 overexpression as an indicator of p53 mutation in this context. The association of both gene mutation and protein accumulation with clinicopathological findings and survival was also studied. A total of 77 samples from 30 esophagectomy specimens with Barrett's esophagus and adenocarcinoma of patients in longitudinal clinical follow-up were analyzed. Different lesions (intestinal metaplasia, dysplasia, and adenocarcinoma) as well as normal squamous-cell esophageal epithelia were sampled from formalin-fixed, paraffin-embedded tissues by microdissection. Mutations in p53 Exons 5 to 9 were detected by polymerase chain reaction-single-strand conformation polymorphisms (PCR-SSCP) and confirmed by direct DNA sequencing. Nuclear accumulation of p53 protein was analyzed immunohistochemically from tissue sections adjacent to those used for microdissection. p53 gene mutations were found in 17 and p53 protein accumulation were found in 20 tumor samples. Of the 17 adenocarcinomas with a p53 mutation, 16 stained positive for p53 protein. p53 mutations were detected significantly more frequently in high-grade dysplastic than in low-grade dysplastic lesions (77% versus 29%, P < 0.01). In contrast, nuclear accumulation of p53 was detected in 85% of high-grade and 71% of low-grade dysplastic lesions. In eight cases with p53 mutation, the mutation identified in the tumors was also detected in premalignant lesions, mainly in high-grade dysplasia. In four cases of p53-mutated tumors, clones with different p53 mutations were detected in premalignant lesions. Neither p53 mutations nor p53 protein accumulations were found in metaplastic lesions. In summary, we found that p53 mutations occurred mainly during the transition from low-grade to high-grade dysplasia in the neoplastic progression of Barrett's esophagus but not in the nondysplastic Barrett's mucosa. Mutational analysis of p53 by PCR-SSCP and p53 accumulation by immunohistochemistry were mostly concordant in adenocarcinoma and high-grade dysplastic lesions but frequently discordant in low-grade dysplastic lesions. No correlation between p53 gene mutation or p53 accumulation and clinicopathological findings was observed in this study.
Similar articles
-
P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.Clin Cancer Res. 2000 Aug;6(8):3153-8. Clin Cancer Res. 2000. PMID: 10955797 Clinical Trial.
-
High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.Virchows Arch. 2003 Jan;442(1):18-24. doi: 10.1007/s00428-002-0674-1. Epub 2002 Sep 24. Virchows Arch. 2003. PMID: 12536310
-
p53 in esophageal adenocarcinoma: a critical reassessment of mutation frequency and identification of 72Arg as the dominant allele.Int J Oncol. 2007 Dec;31(6):1351-5. Int J Oncol. 2007. PMID: 17982662
-
Clinical use of p53 in Barrett's esophagus.Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1243-9. doi: 10.1158/1055-9965.EPI-06-0010. Cancer Epidemiol Biomarkers Prev. 2006. PMID: 16835318 Review.
-
The molecular biology of esophageal adenocarcinoma.J Surg Oncol. 2005 Dec 1;92(3):169-90. doi: 10.1002/jso.20359. J Surg Oncol. 2005. PMID: 16299787 Review.
Cited by
-
RACK1 promotes the occurrence and progression of cervical carcinoma.J Clin Lab Anal. 2024 Feb;38(4):e25012. doi: 10.1002/jcla.25012. Epub 2024 Feb 2. J Clin Lab Anal. 2024. PMID: 38305509 Free PMC article.
-
Centrosome amplification arises before neoplasia and increases upon p53 loss in tumorigenesis.J Cell Biol. 2018 Jul 2;217(7):2353-2363. doi: 10.1083/jcb.201711191. Epub 2018 May 8. J Cell Biol. 2018. PMID: 29739803 Free PMC article.
-
Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma.PLoS One. 2017 Nov 7;12(11):e0187667. doi: 10.1371/journal.pone.0187667. eCollection 2017. PLoS One. 2017. PMID: 29112960 Free PMC article.
-
Prognostic and predictive significance of p53 and ATRX in neuroendocrine neoplasms of GIT and pancreas and their utility as an adjunct to accurate diagnosis-An eight-year retrospective study.Indian J Gastroenterol. 2025 Feb;44(1):95-102. doi: 10.1007/s12664-024-01678-z. Epub 2024 Oct 1. Indian J Gastroenterol. 2025. PMID: 39352684
-
Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma.Br J Cancer. 2015 Jun 30;113(1):107-18. doi: 10.1038/bjc.2015.179. Epub 2015 Jun 25. Br J Cancer. 2015. PMID: 26110972 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous